

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia

Neil D. Woodward¹, Scot E. Purdon², Herbert Y. Meltzer³ and David H. Zald¹

¹ Department of Psychology, Vanderbilt University, Nashville, TN, USA

² Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada

³ Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN, USA

Abstract

Cognitive impairment is a core feature of schizophrenia and a major impediment to social and vocational rehabilitation. A number of studies have claimed cognitive benefits from treatment with various atypical antipsychotic drugs (APDs). The currently available evidence supporting cognitive improvement with atypical APDs was evaluated in two meta-analyses. Studies that (1) prospectively examined cognitive change to the atypical APDs clozapine, olanzapine, quetiapine, and risperidone, (2) included a commonly used neuropsychological test, and (3) provided data from which relevant effect sizes could be calculated, were included. Forty-one studies met these criteria. Neuropsychological test data from each study were combined into a Global Cognitive Index and nine cognitive domain scores. Two meta-analyses were carried out. The first included 14 controlled, random assignment trials that assigned subjects to an atypical APD and a typical APD control arm. The second analysis included all prospective investigations of atypical treatment and the within-group change score divided by its standard deviation served as an estimate of effect size (ES). The first analysis revealed that atypicals are superior to typicals at improving overall cognitive function (ES=0.24). Specific improvements were observed in the learning and processing speed domains. The second analysis extended the improvements to a broader range of cognitive domains (ES range=0.17–0.46) and identified significant differences between treatments in attention and verbal fluency. Moderator variables such as study blind and random assignment influence results of cognitive change to atypical APDs. Atypical antipsychotics produce a mild remediation of cognitive deficits in schizophrenia, and specific atypicals have differential effects within certain cognitive domains.

Received 14 July 2004; Reviewed 28 September 2004; Revised 21 October 2004; Accepted 27 October 2004

Key words: Atypical antipsychotics, meta-analysis, neuropsychology, schizophrenia.

Introduction

Cognitive dysfunction is fundamental to schizophrenia (Bleuler, 1950; Kraepelin and Robertson, 1919) and readily demonstrated on a variety of neuropsychological instruments (Kolb and Whishaw, 1983). Patients with schizophrenia typically perform one to two standard deviations below normal on a variety of measures, especially those that assess executive functions, verbal skills, processing speed, and attention (Bilder et al., 2000; Fuller et al., 2002; Heinrichs and Zakzanis, 1998; Hoff et al., 1992; Saykin et al., 1994). Cognitive impairment in schizophrenia relates directly

to socio-vocational functioning (Green, 1996; Green et al., 2000), and exerts a greater influence on functional outcome than the presence or severity of the positive or negative symptoms of schizophrenia (Velligan et al., 2000). Furthermore, associations between particular cognitive skills and specific dimensions of outcome have been articulated. Thus, the relationships between cognitive impairments and psychosocial deficits may provide a basis for the prediction of functional changes that should result from treatment-specific changes in cognitive status.

After many years of null results with typical antipsychotic drugs (APDs), and an early negative study of the effect of clozapine on cognition (Goldberg et al., 1993), a series of studies identified significant improvements in cognition with other atypical APDs in addition to clozapine (Bilder et al., 2002; Galletly et al., 1999; Hager et al., 1993; Meltzer and McGurk, 1999;

Address for correspondence: N. D. Woodward, M.A., Department of Psychology, Vanderbilt University, Nashville, TN, 37203, USA.

Tel.: (615) 343-1446 Fax: (615) 343-8449

E-mail: neil.woodward@vanderbilt.edu

Purdon et al., 2000, 2001a; Rossi et al., 1997). As will be discussed, the cognitive enhancement reported in these early studies could have been artifacts related to repeated testing, study characteristics, or other potential biases. Alternatively, the apparent cognitive enhancement may be related to one or more of the following effects of the atypical APDs which are not shared by typical APDs: (1) increased release of dopamine (DA) and acetylcholine (ACh) in the prefrontal cortex and hippocampus (Ichikawa et al., 2002; Kuroki et al., 1999; Parada et al., 1997; Shirazi-Southall et al., 2002); (2) antagonism of 5-HT_{2A}, 5-HT_{2C} or 5-HT₆ receptors (Meltzer, 1999); and (3) stimulation of 5-HT_{1A} receptors (Ichikawa et al., 2001). Increased release of DA may lead to stimulation of D₁ and D₃ receptors, in particular, which might have a beneficial effect on cognition, assuming that these receptors are understimulated in schizophrenia. Increased release of ACh might lead to enhancement of M₁, M₄, or α_7 nicotinic acid post-synaptic receptors, all of which have been suggested to be involved in cognitive impairment in schizophrenia (Bymaster et al., 2003; Olincy et al., 1997; Simosky et al., 2003). The atypical APDs also differ from one another in their relative actions on these systems. Clozapine is an M₁ and M₄ agonist, an effect which other atypical APDs lack (Olianas et al., 1999; Zorn et al., 1994). Blockade of M₂ receptors by clozapine or olanzapine in vivo would be expected to increase the release of ACh. Stimulation of M₁ and M₄ receptors has been shown to improve memory and learning in animal models (Felder et al., 2001). Risperidone has a relatively high affinity and long dissociation latency period for D₂ receptors (Kapur and Seeman, 2001; Lavalaye et al., 1999; Seeman, 2002), suggesting that patients receiving risperidone may be more likely to display adverse effects associated with DA antagonism in the striatum including greater extrapyramidal symptoms (EPS) and reduced procedural learning, especially with doses above 6 mg/d. A recent meta-analysis of EPS prevalence in clinical trials and preliminary evidence of reduced procedural learning with risperidone, relative to clozapine and olanzapine, provides support for this prediction (Bedard et al., 2000; Leucht et al., 1999; Purdon et al., 2003). Thus, there are not only neurochemical reasons to expect atypical APDs to improve cognitive function, relative to typical APDs, but differences between treatments within the atypical APD class might also be anticipated.

The significant methodological differences that exist across studies undermine attempts to draw definitive conclusions on the efficacy and differential benefits of atypical APDs to cognition in

schizophrenia. Two earlier quantitative reviews of published studies up to 2000 identified significant gains with atypical APDs in several cognitive domains including verbal fluency, vigilance and selective attention, secondary memory, and visuomotor skills (Harvey and Keefe, 2001; Keefe et al., 1999). Effect sizes, in terms of Cohen's *d*, were typically within the range of 0.20–0.40 suggesting that the improvements may be mild relative to the magnitude of the cognitive deficits seen in patients with schizophrenia. However, the earlier reviews were hampered by the relatively small number of studies that had been carried out prior to 2000, the limited availability of data on olanzapine, and the absence of data on quetiapine. Since the earlier reviews, the results of over 20 studies involving atypical APDs including several large-scale NIMH and industry-sponsored clinical trials have been released and there is now a substantial pool of data on olanzapine's effects on cognition and results from several investigations of quetiapine (Bilder et al., 2002; Harvey et al., 2003; Purdon et al., 2001b; Velligan et al., 2002).

The large number of studies that have been reported since 2000 make it feasible to examine the effects of relevant methodological characteristics, such as medication blind, random assignment of subjects, and study duration. Earlier reviews have stressed the importance of controlling for these variables to protect against experimenter bias and demand characteristics. However, quantitative comparisons between studies that included these design features and those that did not are lacking. Additional study variables that may be relevant include baseline medication status and medication dosage used in typical control arms. Several investigators have speculated that the cognitive improvements observed with atypical APDs may reflect an avoidance of potentially deleterious effects associated with typical APD treatments rather than a novel enhancement of cognition (Carpenter and Gold, 2002). Definitive support for this contention is lacking although recent investigations suggest that haloperidol may indeed interfere with specific cognitive skills such as processing speed and procedural learning (Bedard et al., 1996, 2000; Blyler and Gold, 2000; Purdon et al., 2002, 2003; Sharma and Harvey, 2000; Stevens et al., 2002). In the case of within-subjects switch studies, the absence of an unmedicated baseline assessment does not rule out the possibility that the improvements observed following a switch to an atypical APD treatment reflect a release from the adverse effects associated with a typical APD rather than a benefit of atypical APD treatment.

The larger number of studies now available for review also permits a more thorough investigation of the unique cognitive benefits for each medication and a preliminary examination of potential differences between them. Although several investigations have directly compared medications within the atypical APD class, with few exceptions (Harvey et al., 2003), interpretation of the results have been limited by the small number of subjects included in treatment groups (Bilder et al., 2002; Purdon et al., 2000). By quantitatively analysing effects across studies, meta-analysis can overcome these sample-size limitations, and help identify possible differences between treatments that may warrant further investigation in clinical trials.

At present, over 40 studies have reported on the effects of clozapine, olanzapine, risperidone and quetiapine on a wide range of neuropsychological tests. The studies were entered into a meta-analysis to: (1) evaluate and extend the findings of the earlier meta-analyses; (2) identify any differences between atypical APD medications on cognitive processes; and (3) identify study characteristics that might be relevant to demonstrations of cognitive change.

Methods

Literature search

Relevant articles were identified through extensive literature searches of computerized databases including Medline, PsycInfo, and Dissertation Abstracts. Key search terms included Schizophrenia, Cognition, Neuropsychology, Neurocognition, Clozapine, Olanzapine, Risperidone, and Quetiapine. In addition, the bibliographies of several earlier reviews were examined (Harvey and Keefe, 2001; Keefe et al., 1999; Meltzer and McGurk, 1999; Purdon, 1999, 2000).

Studies were included in the meta-analysis if they met the following criteria: (1) inclusion of patients with a diagnosis of schizophrenia or schizoaffective disorder as outlined in DSM-III, DSM-III-R, DSM-IV, or ICD-9, ICD-10; (2) prospective study design with a baseline assessment and at least one follow-up assessment; (3) trial duration of at least 1 wk; (4) no antipsychotics, except for the study medications were administered; (5) a baseline sample size of at least 10; (6) results of neuropsychological change to treatment were reported for at least one of the common tests listed in Table 1; and (7) the study was published or 'in press' in a peer-reviewed journal as of April 2004. Investigations of geriatric, adolescent (age <18 yr), or high-risk populations were not included. Studies included in the meta-analysis are listed in Table 2.

Table 1. Neuropsychological tests and cognitive domains

	Abbreviation
Vigilance and Selective Attention Continuous Performance Test Stroop Test Trailmaking A	VIG
Working Memory Verbal Working Memory* Spatial Working Memory*	WM
Learning Paragraph Recall Test/WMS-R/ III Logical Memory I Verbal List Learning tests (learning trials) Rey Design Learning Test Rey Complex Figure/WMS-R/ III Visual Reproduction I	LEARN
Cognitive Flexibility and Abstraction Wisconsin Card Sorting Test WAIS-R/III Similarities	CF &A
Processing Speed WAIS R/III Digit Symbol Substitution/Digit Symbol Modalities Test Trailmaking B WISC-R Maze Subtest	PS
Verbal Fluency Controlled Oral Word Test Category Instance Generation Test	VF
Visuospatial Processing WAIS-R/III Block Design Complex Figure Test (copy) Tests of Visual Organization*	VIS
Motor Skills Finger Tapping Test Grooved Pegboard Test/PIN Test	MOTOR
Delayed Recall Paragraph Recall Test/WMS-R/ III Logical Memory II Verbal List Learning tests (delayed free recall) Rey Complex Figure (delayed)/ WMS-R/III Visual Reproduction II	DEL.R.

* See text for additional information.

Coding of study characteristics

Studies were coded for author and year of publication, corporate sponsorship, schizophrenia subtype classification, baseline medication status, medication blind, random assignment, trial medications, total subjects

Table 2. Studies included in the meta-analysis

Bilder et al. (2002)	Green et al. (1997)	Lindenmayer et al. (1998)	Rossi et al. (1997)
Buchanan et al. (1994)	Green et al. (2002)	Liu et al. (2000)	Rybakowski and
Chua et al. (2001)	Hagger et al. (1993)	Ljubin et al. (2000)	Borkowska (2001)
Cuesta et al. (2001)	Harvey et al. (2000)	Manschreck et al. (1999)	Sax et al. (1998)
Fleming et al. (2001)	Harvey et al. (2003)	McGurk et al. (1997)	Schall et al. (1998)
Fuji et al. (1997)	Harvey et al. (2004)	Meltzer and McGurk (1999)	Sharma et al. (2003)
Galletly et al. (1997)	Hoff et al. (1996)	Potkin et al. (2001)	Smith et al. (2001)
Galletly et al. (2000)	Hong et al. (2002)	Purdon et al. (2000)	Stip and Lussier (1996)
Goldberg et al. (1993)	Keefe et al. (2004)	Purdon et al. (2001a)	Stip et al. (2003)
Good et al. (2002)	Kern et al. (1999)	Purdon et al. (2001b)	Velligan et al. (2002)
Grace et al. (1996)	Lee et al. (1999)	Rosenheck et al. (2003)	Velligan et al. (2003)

completing baseline cognitive assessment and the number completing the trial, trial duration, and mean trial medication dosages. Schizophrenia subtype classification was based on explicit descriptions contained in each publication and consisted of three classifications: general schizophrenia, early phase, or treatment refractory. Medication blind was coded as double blind or open label. Open-label extensions to double-blind studies were not included in this analysis with the exception of Smith et al. (2001) which did not report within-group results at the end of the double-blind phase. The number of subjects who completed the study was defined as the total number of subjects for each medication group that completed at least one cognitive test at trial end-point, or last observation carried forward (LOCF). In addition, if a study reported statistics based on the LOCF method, then these values were used to calculate effect sizes.

Neuropsychological tests and domains

Similar to other meta-analyses of cognition in schizophrenia (Harvey and Keefe, 2001; Heinrichs and Zakzanis, 1998) effect sizes were calculated for individual neuropsychological tests, although in several cases highly similar tests were combined into a single measure (e.g. verbal list learning). These effect sizes were then combined into nine domains, as listed in Table 1, by averaging effect sizes within studies across tests that putatively tap similar skills. A Global Cognitive Index was also created by either averaging all domain effect sizes within a study or using Global Cognitive Index scores in cases where studies reported them. Thus, each study contributed one Global Cognitive Index score and at least one domain effect size. The construction of the domains reported here was based upon prior reviews and earlier studies

that utilized large cognitive batteries, contemporary neuropsychological domain constructs, and cognitive domains relevant to outcome in schizophrenia (Bilder et al., 2000, 2002; Green et al., 2000, 2002; Harvey and Keefe, 2001; Heaton et al., 2001; Purdon et al., 2000, 2001b).

The Vigilance and Selective Attention domain included the Continuous Performance/Attention Test, Stroop Test (colour-word score), and Trailmaking A Test.

The Working Memory domain consisted of tests of verbal or spatial working memory. These included the verbal working memory tests Digit Span, Digit Span Distraction, Paced Auditory Serial Addition, Letter-Number Span, and Consonant Trigrams and spatial working memory tests such as the Visual Span subtest of the WAIS-R/III and the Spatial Working Memory Test (Keefe et al., 1995).

The Learning domain included the Rey Serial Design Learning Test (RDLT), paragraph recall tests (WMS-R/III Logical Memory I or the Story Recall Test), verbal list learning tests (California, Crawford, Hopkins or Rey Verbal Learning tests, or the Bushcke Selective Reminding Test), and visual reproduction tests (WMS-R/III Visual Reproduction subtest, the Rey-Osterrieth/Taylor Complex Figure Test (RCFT), or the Benton Visual Retention Test).

The Cognitive Flexibility and Abstraction domain consisted of the Wisconsin Card Sorting Test (perseverative errors or percent perseverative errors score) and the WAIS-R/III Similarities subtest. Timed motor tests occasionally considered to tap executive function (e.g. Trailmaking B) were not included because differential effects of typical and atypical APDs on motor speed might have unduly influenced effect sizes for this domain.

The Processing Speed domain included the WAIS-R/III Digit Symbol Coding or Digit Symbol Modalities

Test, Trailmaking B, and the Wechsler Intelligence Scale for Children – Revised Mazes subtest.

The Verbal Fluency domain consisted of the Controlled Oral Word Association and Category Instance Generation tests.

The Visuospatial Processing domain included the WAIS-R/III Block Design subtest, the Rey-Osterrieth/Taylor Complex Figure Test copy score and visual organization tests such as the Hooper Visual Organization Test, Mooney Face Closure Test, Benton Judgment of Line Orientation, and Line Drawing.

The Motor Skill Domain included the Finger Tapping Test, Grooved Pegboard, and Pin tests.

The Delayed Recall domain included tests of a visual recall (WMS-R/III Visual Reproduction II and the delayed RCFT), verbal recall (WMS-R/III Logical Memory II and delayed Story Recall Test), and verbal list learning (delayed free recall scores from the verbal list learning tests described above).

Calculation of effect sizes and data analysis

Typically, meta-analyses only include controlled studies that randomly assigned subjects to either a control group or an active treatment group. However, this approach would overlook a substantial body of evidence from single-sample studies that may be relevant to the demonstration of cognitive change from atypical APD treatments. In an attempt to preserve scientific rigour without omitting potentially important results, two analyses were undertaken, the first with a conservative approach to the published literature and the second with less conservative restrictions.

Analysis 1

The first analysis included only reports from comparisons of typical APDs and atypical APDs that randomly assigned patients to treatment. Post-treatment means and standard deviations were used to calculate Hedges' g , the difference between the means of atypical APD and typical APD groups at study end-point, divided by their pooled standard deviation. Where group means and standard deviations were not explicitly reported, Hedges' g was calculated using appropriate alternative methods based on t or F statistics (Rosenthal, 1994). Where the t or F statistics were also not reported, data were solicited from the original study authors. A weighted average effect-size estimate was calculated for the Global Cognitive Index and each domain by combining data from all studies that examined cognitive change to clozapine, olanzapine, risperidone, or quetiapine. In cases where a study included more than one atypical APD arm, in addition

to a typical APD control, or multiple dosing arms, the atypical APD arms were treated as separate samples and effect sizes for each arm were calculated. Effect sizes were combined according to the fixed-effects model (Shadish and Haddock, 1994). Briefly, each effect size was weighted by the inverse of its variance such that effect sizes calculated from studies with larger sample sizes contributed more to the overall effect size when combined. A weighted average effect size, with positive values indicating improvement and negative values indicating a decline in performance, and a corresponding Z statistic was calculated to determine if the weighted average effect size was significantly greater than zero. Given the large number of Z tests carried out, a Bonferroni correction was applied to the critical α . For the domains, the critical α was $p=0.006$. In addition, a 95% confidence interval (CI) was calculated for the global and domain effect sizes. To assess the relevance of predefined moderator variables, a measure of effect size homogeneity, the Q statistic, was also calculated for each neuropsychological domain and the Global Cognitive Index (Hedges and Vevea, 1998). The Q statistic has a χ^2 distribution with $k-1$ degrees of freedom, where k is the number of effect sizes being combined. The critical α for the Q statistic was set at 0.05. When the assumption of homogeneity was rejected the effect sizes were combined using the random-effects model. In the moderator variable analysis, the Q statistic was partitioned into a between-groups component, Q_{BET} , and a within-groups component, Q_{W} (analogous to a one-way ANOVA). A moderator variable was considered significant if it effectively separated the effect sizes into separate categories (i.e. Q_{BET} was significant) that did not have significant within-group variation (i.e. Q_{W} was not significant). The R^2 value was also calculated for each significant moderator variable to assess the strength of the relationship between moderator and dependent variables. Moderator variables included the coded study characteristics of baseline medication status (typical APDs vs. unmedicated), schizophrenia subtype classification (early phase combined with general, vs. treatment refractory), and corporate sponsorship of study (yes vs. no). In addition, correlations between effect sizes and the continuous variables haloperidol arm dose at study end-point and study duration were carried out. To avoid violations of independence in the moderator variable analysis, average effect sizes were calculated across groups for the three studies that examined cognitive change in more than one atypical treatment or dosing arm (Bilder et al., 2002; Purdon et al., 2000; Velligan et al., 2002) and for four risperidone studies

that reported results from the same trial (Green et al., 1997; Kern et al., 1998, 1999; McGurk et al., 1997).

Analysis 2

The second analysis included all prospective studies, regardless of whether or not participants were randomly assigned to treatment, including single-sample switch studies. Investigations of cognitive change following a shift from one atypical APD to another were not included. A single sample, within groups, repeated measures index of effect size, the mean change score divided by its standard deviation, analogous to Hedges' g was used as the estimate of effect size (Rosenthal, 1994). It should be noted that this method for calculating effect sizes probably yields different effect sizes than those reported in Analysis 1 since each group acts as its own control in a repeated-measures design. Thus, comparisons between Analyses 1 and 2 should not be made. Paired t tests or alternative repeated-measures values were available to calculate an effect size for the majority of studies. In studies that did not report change scores, an estimate of effect size was derived using the procedure of Smith et al. (1980), which estimates change from the pre-treatment and post-treatment group means, divided by the standard deviations reported in the original manuscript, and adjusted for test-retest correlations provided in a compendium of neuropsychological tests (Spren and Strauss, 1998).

Weighted effect sizes, Z statistics, 95% CIs, and Q statistics were then calculated overall for each domain, and again within each medication group. As in Analysis 1, when the Q statistic was rejected, effect sizes were combined according to the random-effects model.

Analysis 2 had a sufficient number of studies to allow for a more comprehensive examination of the influence that study characteristics might have on effect sizes and comparisons between atypical APDs. Comparisons of the dichotomous variables study blind or random assignment (controlled vs. uncontrolled), corporate sponsorship (yes vs. no), baseline medication status (typical APDs vs. unmedicated), and schizophrenia subtype classification (early phase combined with general, vs. treatment refractory) were carried out as described in Analysis 1. The variables study blind and random assignment were collapsed into a single variable due to the fact that almost every study that randomly assigned subjects to treatment was also double blind. Thus, in order to avoid the redundancy of carrying out two comparisons, studies that included at least one of these features in their design were coded as controlled and those that did not

include either were coded as uncontrolled. Pearson's R correlations were carried out to examine relationships between domain effect sizes and study duration.

In addition, differences in cognitive change between medications were examined. Group differences were examined in the same manner as moderator variables, by partitioning the Q statistic into a between- and within-groups component where the between-groups component reflects the difference between medication groups and the within-groups component represents an overall measure of the variability within medication groups. In cases where Q_{BET} was significant, pairwise contrasts were carried out to identify specific differences between medication groups. A weighted within medication group effect size was not included in the pairwise contrasts if it was calculated under the random-effects model. The critical α for the pairwise contrasts was Bonferroni corrected to control for Type I error.

Results

Analysis 1

Study demographics

Seventeen studies from 14 independent, controlled, random-assignment clinical trials were included in the analysis. The discrepancy between the number of studies and number of clinical trials is due to the fact that four studies reported on the same clinical trial of cognitive change to risperidone (Green et al., 1997; Kern et al., 1998, 1999; McGurk et al., 1997). Two studies were open label. Of the 14 independent trials, two included a clozapine arm, three included an olanzapine arm, four included a risperidone arm, two included a quetiapine arm, one included clozapine, olanzapine, and risperidone arms, one included both a risperidone and an olanzapine arm, and one included two different dose groups of quetiapine. Schizophrenia subtype classification for the 14 trials was early phase ($n=3$), general ($n=7$), and treatment refractory ($n=4$). Baseline medication status included unmedicated ($n=5$) or predominantly unmedicated ($n=1$), medicated ($n=7$), and mixed (predominantly haloperidol, $n=1$). The reported washout period for the unmedicated studies typically ranged from 2 to 7 d. After excluding four reports from the same clinical trial because of discrepancies in the reported number of enrolled subjects (Green et al., 1997; Kern et al., 1998, 1999; McGurk et al., 1997), the 13 remaining (independent) trials reported retention rates of 43–93% of enrolled patients. As expected, attrition was lower in studies with a short duration of treatment and

Table 3. Neuropsychological change with atypical antipsychotic drugs: Analysis 1

	Number of effect sizes (<i>k</i>) and number of subjects (<i>n</i>)										Overall weighted ES			
	Clozapine		Olanzapine		Risperidone		Quetiapine		Total		ES	95% CI	Z statistic	<i>p</i> value
	<i>k</i>	<i>n</i>	<i>k</i>	<i>n</i>	<i>k</i>	<i>n</i>	<i>k</i>	<i>n</i>	<i>k</i>	<i>n</i>				
Global Cognitive Index	3	73	6	254	5	116	4	71	18	514	0.24	0.11 to 0.37	3.67	<0.001
Vigilance and Selective Attention	2	43	3	122	4	92	3	59	12	316	0.12	−0.04 to 0.28	1.43	0.152
Working Memory	2	53	3	135	4	87	1	11	10	286	0.05	−0.12 to 0.22	0.60	0.546
Learning	2	54	4	220	4	97	4	71	14	442	0.24	0.10 to 0.38	3.44	<0.001
Processing Speed	3	71	5	233	4	93	3	54	15	451	0.21	0.07 to 0.35	3.02	0.003
Cognitive Flexibility and Abstraction	3	72	6	243	3	62	2	28	14	405	0.04	−0.10 to 0.18	0.55	0.581
Verbal Fluency	3	72	5	242	3	65	4	71	15	449	0.16	0.02 to 0.30	2.26	0.024
Visuospatial Processing	2	43	4	134	3	65	1	11	10	253	0.00	−0.18 to 0.18	0.02	0.988
Motor Skill	1	24	4	222	3	65	1	11	9	322	0.21	0.05 to 0.37	2.56	0.010
Delayed Recall	3	72	3	201	2	58	2	43	10	374	0.13	−0.02 to 0.28	1.69	0.091

ES, Effect size; CI, confidence interval.

retention improved to a range of 50–93% of enrolled subjects when the last observation was carried forward for analysis.

Mean trial duration was 31 wk (median=23 wk) and ranged from 4 to 104 wk. The range of average doses used for each medication was consistent with doses recommended in the various product monographs; clozapine (410.5–521.8 mg), olanzapine (10.6–30 mg), risperidone (5.7–11.3 mg), and quetiapine (300–600 mg). The average dose used in the haloperidol control arms ranged from 4.5 to 37.9 mg.

Effect sizes

Effect sizes for one study could not be computed from the information provided by the author (Kern et al., 1998) and effect sizes for three studies were based on LOCF data. The effect size for the Global Cognitive Index was significant [effect size (ES)=0.24, Z=3.67, *p*<0.001] indicating that atypical APDs improved overall cognitive function to a greater extent than typical APDs. The effect sizes for the Learning (ES=0.24, Z=3.44, *p*<0.001) and Processing Speed (ES=0.21, Z=3.02, *p*<0.003) domains were significant at the Bonferroni-corrected level. Additional improvements at the uncorrected significance level were observed for the Verbal Fluency (ES=0.16, Z=2.26,

p<0.024) and Motor Skill (ES=0.21, Z=2.56, *p*<0.010) domains. The weighted mean effect sizes for the nine domains and the Global Cognitive Index are presented in Table 3. In addition, the number of subjects within each atypical medication group, summed across studies, is reported for each cognitive domain.

Moderator variable analysis

None of the moderator variables was significantly associated with the Global Cognitive Index (all *Q*_{BET} *p* values >0.58). Study duration and haloperidol dose used in the control arm were not significantly correlated with the Global Cognitive Index score, all Pearson’s *p* values >0.44. Similarly, none of the moderator variables tested was associated with any domain score (all *Q*_{BET} <3.28, *p*>0.070). Effect sizes for the Cognitive Flexibility and Abstraction domain were negatively correlated with trial duration (*r*=−0.70, *p*<0.016), however, it was apparent that this was due to an outlier (Green et al., 2002), that was significantly longer in duration (104 weeks) than the remaining studies. This correlation was not significant after removal of the Green et al. study. There was evidence that effect sizes for Processing Speed were related to the average dose used in the haloperidol control arms (*r*=0.58, *p*<0.031), however, this correlation

Table 4. Neuropsychological change with atypical antipsychotic drug (APDs): Analysis 2

	Number of effect sizes (<i>k</i>), number of subjects (<i>n</i>), mean effect size (ES)														
	Clozapine			Olanzapine			Risperidone			Quetiapine			All atypical APDs combined		
	<i>k</i>	<i>n</i>	ES	<i>k</i>	<i>n</i>	ES	<i>k</i>	<i>n</i>	ES	<i>k</i>	<i>n</i>	ES	<i>k</i>	<i>n</i>	ES
Global Cognitive Index	17	344	0.29*	13	690	0.43*	13	361	0.28*	7	118	0.44*	50	1513	0.36*
Vigilance and Selective Attention	8	152	0.17	9	512	0.47†	9	289	0.12	5	91	0.82†	31	1044	0.35†‡
Working Memory	8	160	0.25	8	406	0.24†	9	281	0.24†	2	27	0.41	27	874	0.25†
Learning	10	210	0.31†	10	625	0.61†‡	7	251	0.41†	6	108	0.24	33	1194	0.46†‡
Processing Speed	16	326	0.35†	12	648	0.43†	9	299	0.30†	6	107	0.35	43	1380	0.38†
Cognitive Flexibility and Abstraction	12	227	0.25	10	471	0.15	4	189	0.10	3	50	0.33	29	937	0.17†
Verbal Fluency	15	319	0.44†	11	651	0.25†	5	207	0.06	6	107	0.63†	37	1284	0.30†
Visuospatial Processing	9	179	0.20	5	144	0.50†	3	65	0.39	1	11	0.56	18	399	0.35†
Motor Skills	4	68	0.64†	5	238	0.25	2	65	0.22	2	34	0.20	13	405	0.30†
Delayed Recall	13	280	0.25†	7	460	0.53†	5	211	0.46†	3	58	0.30†‡	28	1009	0.43†‡

* Effect size > 0, *p* < 0.050.

† Effect size > 0, *p* < 0.006.

‡ Random-effects model used to combine ESs, χ^2 *p* value < 0.05.

did not remain significant when effect sizes were collapsed across groups within the studies that included multiple atypical treatment arms (*r* = 0.50, *p* < 0.15).

Analysis 2

Study demographics

Fifty independent groups from 41 studies met criteria for inclusion in Analysis 2. There were more groups than studies because eight studies included more than one atypical treatment arm or group. The schizophrenia subtype classification included early phase (*n* = 5), general (*n* = 18), and treatment-refractory (*n* = 18) patients. Baseline medication status included unmedicated (*n* = 11), medicated (*n* = 22), mixed (unmedicated/typicals = 1; typical/atypicals = 4), and unknown (*n* = 3). Washout periods for the unmedicated studies typically ranged from 1 to 7 d although one study included only neuroleptic-naive subjects. Eighteen studies either randomly assigned subjects to treatment or were double blind. Eighteen studies received at least partial funding support from a pharmaceutical company. Among the studies that were not included in Analysis 1, the percentage of subjects completing the trials ranged from 45% to 100%. As expected the average percentage was high, 82%, possibly reflecting the tendency for less controlled studies to infrequently report the number of subjects initially screened or enrolled in a study. Mean trial duration was 25 wk (median = 14 wk) and ranged from 1.5 wk to 3 yr. The mean and range (in parentheses) of doses under double-blind (DB) conditions tended to be lower than the open-label (OL) doses in studies of clozapine [DB = 454.3 (410.5–498), OL = 478.4 (200–719)], and quetiapine [DB = 424.5 (300–600), OL = 529.1 (319.3–750)], whereas the reverse was true for olanzapine [DB = 16.9 (10–30), OL = 13.8 (11–19.9)], and risperidone [DB = 7.7 (5.7–11.3), OL = 5.5 (2.2–8.9)].

Effect sizes

The results for Analysis 2 are shown in Table 4. The Global Cognitive Index for all atypical treatments combined was significantly greater than zero (ES = 0.36, *Z* = 8.87, *p* < 0.001). All cognitive domains demonstrated significant improvement on atypical APD medications at the Bonferroni-corrected significance level. The weighted effect sizes for the nine domains ranged from 0.17 to 0.46. The weighted effect sizes for the Vigilance and Selective Attention, Learning, and Delayed Recall domains were calculated under the random-effects model due to the presence of significant heterogeneity (all χ^2 *p* values < 0.010). Inspection




Figure 1. Neuropsychological change to atypical anti-psychotic drugs: controlled (■) vs. uncontrolled studies (□). * Indicates significant differences between controlled and uncontrolled trials ($p < 0.05$). For abbreviations see Table 1.

of the distribution of effect sizes within the Learning domain revealed an outlier ($ES = 1.22$) that was significantly greater than the range of the remaining effect sizes ($ES = -0.13$ – 0.84). Removal of this outlier significantly reduced the variation within the Learning domain ($\chi^2_{df=32} = 28.95$, $p < 0.622$) and the mean effect size remained significant ($ES = 0.43$, $Z = 9.94$, $p < 0.001$). This outlier is not included in the moderator or comparisons between treatment groups' analyses below.

Moderator variables

Global Cognitive Index effect sizes from uncontrolled studies ($ES = 0.43$, $Z = 6.75$, $p < 0.001$) were marginally larger than those from controlled studies ($ES = 0.32$, $Z = 6.03$, $p < 0.001$), however, this difference was not significant, $Q_{BET} = 1.95$, $p < 0.164$. The moderator variable, control, was significantly associated with Verbal Fluency ($Q_{BET} = 8.19$, $p < 0.005$; $Q_W = 32.39$, $p < 0.595$; $R^2 = 0.18$) and Processing Speed effect sizes ($Q_{BET} = 6.82$, $p < 0.009$; $Q_W = 47.73$, $p < 0.252$; $R^2 = 0.11$). Verbal Fluency effect sizes calculated from random assignment or double-blind studies were significantly less than those obtained from open-label, uncontrolled studies ($ES = 0.21$ vs. 0.45). Similarly, effect sizes for Processing Speed were also larger in the uncontrolled relative to controlled studies ($ES = 0.50$ vs. 0.30). The weighted mean and 95% CI for each domain and the Global Cognitive Index for controlled and uncontrolled studies are displayed in Figure 1. Within the controlled studies, the weighted mean effect size for each domain remained significant after Bonferroni correction, however, the weighted mean effect sizes for the Vigilance and Selective Attention, Cognitive

Flexibility and Abstraction, and Visuospatial Skill domains calculated from uncontrolled studies were not. The moderator variable baseline medication status was significantly associated with Delayed Recall domain effect sizes ($Q_{BET} = 5.98$, $p < 0.015$; $Q_W = 26.29$, $p < 0.240$; $R^2 = 0.14$). Studies that included an unmedicated baseline produced smaller Delayed Recall effect sizes than those that tested subjects while they were receiving typical APDs at baseline ($ES = 0.21$ vs. 0.54). The moderator variables diagnosis, corporate sponsorship, and schizophrenia subtype were not significantly associated with the Global Cognitive Index score or any domain. Trial duration was not correlated with the Global Cognitive Index or any domain effect size.

Comparison of atypical antipsychotic drugs

The Q_{BET} statistic revealed significant group differences within the Vigilance and Selective Attention domain ($Q_{BET} = 22.53$, $p < 0.001$; $Q_W = 26.52$, $p < 0.491$; $R^2 = 0.46$) and the Verbal Fluency domain ($Q_{BET} = 15.47$, $p < 0.002$; $Q_W = 25.18$, $p < 0.912$; $R^2 = 0.32$). Within the Vigilance and Selective Attention domain, follow-up contrasts identified a significant advantage for quetiapine, relative to clozapine ($\chi^2_{df=1} = 11.35$, $p < 0.001$) or risperidone ($\chi^2_{df=1} = 15.47$, $p < 0.001$), and a significant advantage for olanzapine, relative to risperidone ($\chi^2_{df=1} = 10.92$, $p < 0.001$) at the Bonferroni-corrected level [$p = (0.05/6) = 0.008$]. Additional advantages for quetiapine, relative to olanzapine ($\chi^2_{df=1} = 4.19$, $p < 0.041$), and olanzapine, relative to clozapine ($\chi^2_{df=1} = 5.41$, $p < 0.021$), were observed at the uncorrected significance level. Pairwise contrasts within the Verbal Fluency domain indicated that quetiapine improved performance to a greater extent than risperidone ($\chi^2_{df=1} = 11.09$, $p < 0.001$), and clozapine improved verbal fluency to a greater extent than risperidone ($\chi^2_{df=1} = 9.19$, $p < 0.003$) after Bonferroni correction. Additional advantages for quetiapine, compared to olanzapine ($\chi^2_{df=1} = 6.26$, $p < 0.013$), and clozapine, compared to olanzapine ($\chi^2_{df=1} = 3.86$, $p < 0.050$), were observed at the uncorrected significance level. The Verbal Fluency pairwise contrasts were repeated after exclusion of the uncontrolled studies since this moderator variable was associated with verbal fluency effect sizes. After excluding uncontrolled studies, the quetiapine vs. risperidone and quetiapine vs. olanzapine contrasts were significant at the Bonferroni-corrected significance level ($\chi^2_{df=1} = 10.16$, $p < 0.002$ and $\chi^2_{df=1} = 7.54$, $p < 0.007$ respectively) but the clozapine vs. risperidone contrast was not ($\chi^2_{df=1} = 4.50$, $p < 0.034$).

Within-group effect sizes

The within-group effect sizes for each medication are presented in Table 4. Because the moderator control was significant for Verbal Fluency and Processing Speed, the within-group effect sizes for these two domains were recalculated after removing uncontrolled studies. After excluding the uncontrolled studies, the Verbal Fluency effect sizes for clozapine ($ES=0.41$, $Z=2.87$, $p<0.005$), and quetiapine ($ES=0.68$, $Z=3.92$, $p<0.001$) remained significant. However, the Verbal Fluency effect size for olanzapine ($ES=0.17$, $Z=2.54$, $p<0.012$) and the Processing Speed effect sizes for clozapine ($ES=0.28$, $Z=0.99$, $p<0.322$), and risperidone ($ES=0.19$, $Z=2.10$, $p<0.036$) did not. The results for quetiapine should be interpreted cautiously given that the effect sizes for several domains included relatively few studies and, in the case of visuospatial processing, were based on a single study.

Discussion

The findings from the current set of meta-analyses indicate that atypical APDs improve overall cognitive function in schizophrenia and performance in a number of cognitive domains. The results obtained from Analysis 1 of 14 controlled, random-assignment trials indicates that atypical APDs are superior to typical APDs, haloperidol in particular, at improving overall cognitive function. This finding is consistent with an earlier meta-analysis of three randomized, controlled trials that identified improvement in overall cognitive function with atypical APDs. In contrast to the earlier meta-analysis that was based upon a small number of clinical trials conducted prior to 1999, the greater number of studies in the current meta-analysis allowed for a closer examination of the improvements. After Bonferroni correction, improvements were identified in learning and processing speed. Additional improvements in verbal fluency and motor skill were detected, although these improvements failed to reach Bonferroni-corrected significance levels.

The inclusion of investigations with single treatment arms and uncontrolled designs in Analysis 2 further supports the benefits of atypical APD treatments and indicates improvements occur in a wide array of cognitive functions. The effect sizes for domains ranged from 0.17 to 0.46 and are remarkably consistent with Harvey and Keefe's (2001) earlier review of 20 studies. For example, Harvey and Keefe (2001) identified improvements, in terms of Cohen's d , of 0.39 and 0.18 for vigilance and executive functions respectively. The results reported here for Vigilance

and Selective Attention and Cognitive Flexibility and Abstraction were 0.34 and 0.17.

A primary advantage of the meta-analytical strategy involves the ability to analyse moderator variables. There was no compelling evidence that moderator variables influenced effect sizes among the set of randomized, controlled trials. However, a trend emerged for a positive correlation between haloperidol dose and the degree to which the patients treated with atypical APDs outperformed haloperidol-treated patients on processing speed tasks. Although this association failed to reach statistical significance, it suggests that some of the advantages of atypical APDs relates to an avoidance of the deleterious effects of high doses of haloperidol. Alternatively, one might speculate that this association reflects symptom severity, with the most severe patients requiring the highest treatment doses, and the most severe subjects showing the greatest relative advantage of atypical APDs.

Examination of moderator variables in Analysis 2 revealed that studies that failed to randomly assign subjects to treatment or utilized open-label designs produced larger verbal fluency and processing speed effect sizes than studies that included either of these features in their design. However, caution is warranted when interpreting these findings, particularly with respect to verbal fluency, because the larger number of clozapine studies within the group of open-label studies may have skewed the results. Clozapine, in contrast to olanzapine and risperidone, significantly improves verbal fluency in both open-label and double-blind studies and it is possible that the higher number of open-label clozapine studies may have inflated the mean effect size. The Global Cognitive Index was not significantly different between controlled and uncontrolled studies suggesting that study methodology does not systematically bias all results. Rather, the effects of study design appear to increase the variability of effects across studies as evidenced by the fact that, within any given domain, uncontrolled studies yielded a broader range of effect sizes than the controlled studies.

Pairwise contrasts between atypical APDs indicated that no medication appeared superior or inferior to the other medications in overall cognitive function, but several differences emerged in two domains, Vigilance and Selective Attention, and Verbal Fluency. The findings should be considered preliminary until more large-scale, controlled comparisons between atypical APDs are carried out, particularly with clozapine and quetiapine. However, the results are generally consistent with predictions derived from the assumption

that lower dopamine D2 receptor affinity and increased serotonergic effects may be related to cognitive benefits from novel agents. In contrast the results are not entirely consistent with the longstanding assumption that the inherent anticholinergic properties of some APDs might limit gains in memory and attention (McGurk and Powchick, 2000). Risperidone, which has the highest affinity for D2 receptors among the atypical agents (Schotte et al., 1996; Seeman, 2002), showed the least beneficial profile on measures of Vigilance and Selective Attention and Verbal Fluency, being outperformed by quetiapine and olanzapine on Vigilance and Selective Attention, and quetiapine and clozapine on Verbal Fluency. The differences were quite robust ranging from 0.3 to 0.5 standard deviations and, for Verbal Fluency, remained significant even when the analysis was restricted to controlled studies. Clozapine, which may be more cholinomimetic than anticholinergic (Olianas et al., 1999; Zorn et al., 1994), did not significantly improve Vigilance and Selective Attention and it resulted in less improvement than quetiapine on this domain. Moreover, although clozapine significantly improved Delayed Recall, improvement in this domain was markedly less than that observed in the olanzapine and risperidone groups. However, despite the presumption of significant inherent anticholinergic activity, olanzapine did not conform to this model. Olanzapine treatment produced medium to large gains on tests of vigilance and selective attention and delayed recall. It thus appears that, at least at clinically relevant dosages, olanzapine does not appear to behave like an anticholinergic agent. These conclusions are consistent with the absence of further cognitive impairment observed in patients with Alzheimer's disease treated with very low doses of olanzapine (Kennedy et al., 2001; Street et al., 2000) and the lower incidence of cholinergic-related side-effects and serum anticholinergic levels observed with olanzapine relative to clozapine (Chengappa et al., 2000; Eschweiler et al., 2002).

The moderator analysis is an effective method for detecting systematic variability between different studies of cognitive change to novel treatments, but it does not allow an assessment of more systemic challenges to the validity of the cognitive benefits reported from atypical APDs relative to typical APDs or to the validity of differential benefits within the atypical APD class. One factor especially germane to the current review is the adjunctive use of anticholinergic medications. In studies with a typical APD control arm, emergent EPS require adjunctive anticholinergic medication that may interfere with cognitive skills, particularly attention and memory. It is notable in this

regard that delayed recall scores showed the largest improvements with atypical APDs in studies in which subjects were originally assessed while on a typical APD.

A second artifact relates to the possibility of practice effects that could occur on neuropsychological measures that are repeatedly administered to the same subject. In atypical APD vs. typical APD studies, practice effects would be expected in both treatment arms, thus, a relative advantage of atypical APDs would probably not be related to practice effects alone. However, this inference relies on the unsupported assumption that there will be no interaction between treatment and practice (Carpenter and Gold, 2002). To the contrary, emerging evidence suggests that typical APD treatments may have subtle, detrimental effects on cognition that may limit the benefit of repeated exposure to the same materials (Blyler and Gold, 2000). For example, normalization of procedural learning following a change from atypical APDs to clozapine suggest that some improvements in cognitive function may relate to a release from impairment caused by the typical APD (Purdon et al., 2002). Similar demonstrations of a preservation of procedural learning with olanzapine and clozapine compared to the apparent loss of procedural learning induced by haloperidol, and perhaps risperidone (Bedard et al., 1996, 2000; Purdon et al., 2003; Stevens et al., 2002) support the view that some of the improvements with atypical APDs might result from an avoidance of deleterious effects on learning associated with typical APDs. While typical APDs may limit practice effects, the improvements on atypical APDs are unlikely to be entirely explained by practice effects. The percentage of patients demonstrating improvements at or greater than half a standard deviation, which ranges from 40% to 75%, in recent double-blind, controlled trials (Bilder et al., 2002; Harvey et al., 2003; Velligan et al., 2003) exceeds what one would expect from typical practice effects. Moreover, the differences between atypicals on verbal fluency and attention in the current study can not be accounted for by practice effects.

As with any meta-analysis, publication bias, especially among studies sponsored by pharmaceutical companies, poses a threat to the validity of the findings. Corporate sponsorship plays a significant role in the dissemination of results and although there was no evidence that sponsored trials reported larger effect sizes, it remains possible that a number of sponsored, unpublished negative trials exist. Selective reporting of results within published papers can also pose a threat. However, almost all of the trials included in

the current review examined multiple dependent measures simultaneously and reported all the results within a single article, although there were exceptions (see Green et al., 1997; Kern et al., 1998, 1999; McGurk et al., 1997 for exceptions). Thus, while we cannot rule out the existence of unpublished negative findings, within the published studies analysed here, it seems unlikely that a systematic positive reporting bias exists.

The improvements in cognitive performance with atypical APDs are in general encouraging, especially when the potential implications for socio-vocational re-integration are considered. The gains observed in learning may be particularly relevant as this cognitive skill has been linked to three major dimensions of outcome including community/daily activities, social problem solving/instrumental skills, and psychosocial skill acquisition (Green, 1996; Green et al., 2000). However, it is prudent to conclude this discussion with emphasis on the relatively small magnitude of the observed changes. Schizophrenia patients typically score more than a standard deviation below healthy controls on many of the neuropsychological tests reviewed here (Heinrichs and Zakzanis, 1998). As a class, atypical APDs improve overall cognitive function but the improvement is typically in the range of 0.20–0.40 standard deviations. It is highly unlikely that the gains will be sufficient to return patients to the vocational level predicted from their individual pre-morbid status. However, the medication-specific effects of particular atypical APDs on particular cognitive domains could be relevant to the design of individual treatment plans that take into account the patient's pre-morbid intellect, unique profile of cognitive impairment, prior vocational achievements, and long-term socio-vocational aspirations.

Acknowledgements

The authors thank Dr Sohee Park and Dr Bahr Weiss for their helpful comments on an earlier draft of this manuscript. The authors also thank all the researchers who kindly provided additional study data upon request.

Statement of Interest

Mr Neil D. Woodward, M.A. and Dr David H. Zald, Ph.D. have no affiliation or financial or other relationships with any organization with a financial interest in the subject matter or material discussed in the manuscript. Dr Scot E. Purdon, Ph.D. has received grant/research support, served on an advisory board and/or

as a speaker for Eli Lilly & Co. Dr Herbert Y. Meltzer, M.D. has served as a consultant, board member and/or speaker for Janssen, Novartis, and Pfizer and has received grant/research support from AstraZeneca, Eli Lilly & Co., Janssen, Novartis, and Pfizer. No financial support for this manuscript was received from any manufacturer of the pharmaceutical products discussed in this review.

References

- Bedard MA, Scherer H, Delorimier J, Stip E, Lalonde P** (1996). Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients. *Canadian Journal of Psychiatry* 41, S21–S24.
- Bedard MA, Scherer H, Stip E, Cohen H, Rodriguez JP, Richer F** (2000). Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. *Brain and Cognition* 43, 31–39.
- Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA** (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. *American Journal of Psychiatry* 157, 549–559.
- Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA** (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *American Journal of Psychiatry* 159, 1018–1028.
- Bleuler E** (1950). *Dementia Praecox or, the Group of Schizophrenias*. New York: International Universities Press.
- Blyler CR, Gold JM** (2000). Cognitive effects of conventional antipsychotics: another look. In: Sharma T, Harvey PD (Eds.), *Cognitive Functioning in Schizophrenia: Characteristics, Correlates, and Treatment* (pp. 241–265). Oxford, UK: Oxford University Press.
- Buchanan RW, Holstein C, Breier A** (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. *Biological Psychiatry* 36, 717–725.
- Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL** (2003). Muscarinic mechanisms of antipsychotic atypicality. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 27, 1125–1143.
- Carpenter WT, Gold JM** (2002). Another view of therapy for cognition in schizophrenia. *Biological Psychiatry* 51, 969–971.
- Chengappa KN, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS, Zoretich RA** (2000). Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. *Journal of Clinical Psychopharmacology* 20, 311–316.
- Chua L, Chong SA, Pang E, Ng VP, Chan YH** (2001). The effect of risperidone on cognitive functioning in a sample

- of Asian patients with schizophrenia in Singapore. *Singapore Medical Journal* 42, 243–246.
- Cuesta MJ, Peralta V, Zarzuela A** (2001). Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. *Schizophrenia Research* 48, 17–28.
- Eschweiler GW, Bartels M, Langle G, Wild B, Gaertner I, Nickola M** (2002). Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine? *Pharmacopsychiatry* 35, 96–100.
- Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, Hamilton SE, Gomez J, Wess J, McKinzie DL** (2001). Elucidating the role of muscarinic receptors in psychosis. *Life Sciences* 68, 2605–2613.
- Fleming K, Thyrum P, Yeh C, Vargo DL, Potkin SG** (2001). Cognitive improvements in psychotic subjects treated with 'Seroquel' (quetiapine fumarate): an exploratory study. *Journal of Clinical Psychopharmacology* 21, 527–529.
- Fujii DE, Ahmed I, Jokumsen M, Compton JM** (1997). The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. *Journal of Clinical Neuropsychiatry and Clinical Neuroscience* 9, 240–245.
- Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC** (2002). Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. *American Journal of Psychiatry* 159, 1183–1189.
- Galletly CA, Clark CR, McFarlane AC, Weber DL** (1997). Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. *Psychiatry Research* 72, 161–166.
- Galletly CA, Clark CR, McFarlane AC, Weber DL** (1999). Effects of clozapine for non-treatment-resistant patients with schizophrenia. *Psychiatric Services* 50, 101–103.
- Galletly CA, Clark CR, McFarlane AC, Weber DL** (2000). The effect of clozapine on the speed and accuracy of information processing in schizophrenia. *Progress in Neuropsychopharmacology and Biological Psychiatry* 24, 1329–1338.
- Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR** (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. *British Journal of Psychiatry* 162, 43–48.
- Good KP, Kiss I, Buiteman C, Woodley H, Rui Q, Whitehorn D, Kopala L** (2002). Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. *British Journal of Psychiatry* (Suppl. 43), S45–S49.
- Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, Donnelly K, Smith P, Gunn S** (1996). Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. *Psychiatric Services* 47, 41–45.
- Green MF** (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? *American Journal of Psychiatry* 153, 321–330.
- Green MF, Kern RS, Braff DL, Mintz J** (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? *Schizophrenia Bulletin* 26, 119–136.
- Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J** (2002). The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. *Biological Psychiatry* 51, 972–978.
- Green MF, Marshall Jr. BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J** (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? *American Journal of Psychiatry* 154, 799–804.
- Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY** (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. *Biological Psychiatry* 34, 702–712.
- Harvey PD, Green MF, McGurk SR, Meltzer HY** (2003). Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. *Psychopharmacology (Berlin)* 169, 404–411.
- Harvey PD, Keefe RS** (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. *American Journal of Psychiatry* 158, 176–184.
- Harvey PD, Moriarty PJ, Serper MR, Schnur E, Lieber D** (2000). Practice-related improvement in information processing with novel antipsychotic treatment. *Schizophrenia Research* 46, 139–148.
- Harvey PD, Siu CO, Romano S** (2004). Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. *Psychopharmacology (Berlin)* 172, 324–332.
- Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV** (2001). Stability and course of neuropsychological deficits in schizophrenia. *Archives of General Psychiatry* 58, 24–32.
- Hedges LV, Vevea JL** (1998). Fixed- and random-effects models in meta-analysis. *Psychological Methods* 3, 486–504.
- Heinrichs RW, Zakzanis KK** (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology* 12, 426–445.
- Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, Csernansky JG** (1996). The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. *Neuropsychopharmacology* 15, 361–369.
- Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE** (1992). Neuropsychological functioning of first-episode schizophreniform patients. *American Journal of Psychiatry* 149, 898–903.

- Hong KS, Kim JG, Koh HJ, Koo MS, Kim JH, Lee D, Kim E** (2002). Effects of risperidone on information processing and attention in first-episode schizophrenia. *Schizophrenia Research* 53, 7–16.
- Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY** (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. *Neuropsychopharmacology* 26, 325–339.
- Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY** (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. *Journal of Neurochemistry* 76, 1521–1531.
- Kapur S, Seeman P** (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. *American Journal of Psychiatry* 158, 360–369.
- Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davis KL** (1995). A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. *Schizophrenia Research* 17, 25–33.
- Keefe RS, Silva SG, Perkins DO, Lieberman JA** (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. *Schizophrenia Bulletin* 25, 201–222.
- Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelin-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA, and the HGDH Research Group** (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first episode psychosis: a randomized, double blind trial of olanzapine versus haloperidol. *American Journal of Psychiatry* 161, 985–995.
- Kennedy JS, Zagar A, Bymaster F, Nomikos G, Trzepacz PT, Gilmore JA, Rotelli MD, Breier A, Tollefson G** (2001). The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. *International Journal of Geriatric Psychiatry* 16 (Suppl. 1), S24–S32.
- Kern RS, Green MF, Marshall Jr. BD, Wirshing WC, Wirshing D, McGurk S, Marder SR, Mintz J** (1998). Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. *Biological Psychiatry* 44, 726–732.
- Kern RS, Green MF, Marshall Jr. BD, Wirshing WC, Wirshing D, McGurk S, Marder SR, Mintz J** (1999). Risperidone versus haloperidol on secondary memory: can newer medications aid learning? *Schizophrenia Bulletin* 25, 223–232.
- Kolb B, Wishaw IQ** (1983). Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. *Journal of Nervous Disease and Mental Disorder* 171, 435–443.
- Kraepelin E, Robertson GM** (1919). *Dementia Praecox and Paraphrenia*. Edinburgh: Livingstone.
- Kuroki T, Meltzer HY, Ichikawa J** (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. *Journal of Pharmacology and Experimental Therapeutics* 288, 774–781.
- Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA** (1999). Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. *Psychiatry Research* 92, 33–44.
- Lee MA, Jayathilake K, Meltzer HY** (1999). A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. *Schizophrenia Research* 37, 1–11.
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W** (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophrenia Research* 35, 51–68.
- Lindenmayer JP, Iskander A, Park M, Aperi FS, Czobor P, Smith R, Allen D** (1998). Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. *Journal of Clinical Psychiatry* 59, 521–527.
- Liu SK, Chen WJ, Chang CJ, Lin HN** (2000). Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. *Neuropsychopharmacology* 22, 311–319.
- Ljubin T, Zakic MD, Mimica N, Folnegovic-Smalc V, Makaric G** (2000). A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. *Human Psychopharmacology* 15, 513–519.
- Manschreck TC, Redmond DA, Candela SF, Maher BA** (1999). Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. *Journal of Clinical Neuropsychiatry and Clinical Neuroscience* 11, 481–489.
- McGurk S, Green MF, Wirshing WC, Ames DC, Marshall Jr. BD, Marder SR, Mintz JM** (1997). The effects of risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trial making test. *CNS Spectrums* 2, 60–64.
- McGurk S, Powchick P** (2000). The central cholinergic system and cognitive dysfunction in schizophrenia. In: Sharma T, Harvey PD (Eds.), *Cognitive Functioning in Schizophrenia: Characteristics, Correlates, and Treatment*. Oxford, UK: Oxford University Press.
- Meltzer HY** (1999). The role of serotonin in antipsychotic drug action. *Neuropsychopharmacology* 21, 106S–115S.
- Meltzer HY, McGurk SR** (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. *Schizophrenia Bulletin* 25, 233–255.
- Olianas MC, Maullu C, Onali P** (1999). Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. *Neuropsychopharmacology* 20, 263–270.

- Olinicy A, Young DA, Freedman R** (1997). Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. *Biological Psychiatry* 42, 1–5.
- Parada MA, Hernandez L, Puig DP, Rada P, Murzi E** (1997). Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. *Journal of Pharmacology and Experimental Therapeutics* 281, 582–588.
- Potkin SG, Fleming K, Jin Y, Gulasekaram B** (2001). Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. *Journal of Clinical Psychopharmacology* 21, 479–483.
- Purdon SE** (1999). Cognitive improvement in schizophrenia with novel antipsychotic medications. *Schizophrenia Research* 35 (Suppl.), S51–S60.
- Purdon SE** (2000). Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. *Journal of Psychiatry and Neuroscience* 25, 108–116.
- Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD** (2000). Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. *Archives of General Psychiatry* 57, 249–258.
- Purdon SE, Labelle A, Boulay L** (2001a). Neuropsychological change in schizophrenia after 6 weeks of clozapine. *Schizophrenia Research* 48, 57–67.
- Purdon SE, Malla A, Labelle A, Lit W** (2001b). Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. *Journal of Psychiatry and Neuroscience* 26, 137–149.
- Purdon SE, Woodward N, Lindborg SR, Stip E** (2003). Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. *Psychopharmacology (Berlin)* 169, 390–397.
- Purdon SE, Woodward ND, Mintz A, Labelle A** (2002). Procedural learning improvements after six weeks of clozapine treatment. *Schizophrenia Research* 53, 165–166.
- Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V** (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. *Journal of the American Medical Association* 290, 2693–2702.
- Rosenthal R** (1994). Parametric measures of effect size. In: Cooper HM, Hedges LV (Eds.), *The Handbook of Research Synthesis* (pp. 231–244). New York: Russell Sage Foundation.
- Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M** (1997). Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. *Acta Psychiatrica Scandinavica* 95, 40–43.
- Rybakowski JK, Borkowska A** (2001). The effect of treatment with risperidone, olanzapine, or phenothiazines on cognitive functions in patients with schizophrenia. *International Journal of Psychiatry in Clinical Practice* 5, 249–256.
- Sax KW, Strakowski SM, Keck Jr. PE** (1998). Attentional improvement following quetiapine fumarate treatment in schizophrenia. *Schizophrenia Research* 33, 151–155.
- Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC** (1994). Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. *Archives of General Psychiatry* 51, 124–131.
- Schall U, Catts SV, Chaturvedi S, Liebert B, Redenbach J, Karayanidis F, Ward PB** (1998). The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures. *International Journal of Neuropsychopharmacology* 1, 19–29.
- Schotte A, Janssen PF, Bonaventure P, Leysen JE** (1996). Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. *Histochemical Journal* 28, 791–799.
- Seeman P** (2002). Atypical antipsychotics: mechanism of action. *Canadian Journal of Psychiatry* 47, 27–38.
- Shadish WR, Haddock CK** (1994). Combining estimates of effect size. In: Cooper HM, Hedges LV (Eds.), *The Handbook of Research Synthesis* (pp. 261–282). New York: Russell Sage Foundation.
- Sharma T, Harvey PD** (2000). *Cognition in Schizophrenia: Impairments, Importance, and Treatment Strategies*. Oxford, UK: Oxford University Press.
- Sharma T, Hughes C, Soni W, Kumari V** (2003). Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. *Psychopharmacology (Berlin)* 169, 398–403.
- Shirazi-Southall S, Rodriguez DE, Nomikos GG** (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. *Neuropsychopharmacology* 26, 583–594.
- Simosky JK, Stevens KE, Adler LE, Freedman R** (2003). Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. *Psychopharmacology (Berlin)* 165, 386–396.
- Smith ML, Glass GV, Miller TI** (1980). *The Benefits of Psychotherapy*. Baltimore: Johns Hopkins University Press.
- Smith RC, Infante M, Singh A, Khandat A** (2001). The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. *International Journal of Neuropsychopharmacology* 4, 239–250.
- Spren O, Strauss E** (1998). *A Compendium of Neuropsychological Tests Administration, Norms, and Commentary*. New York: Oxford University Press.
- Stevens A, Schwarz J, Schwarz B, Ruf I, Kolter T, Czekalla J** (2002). Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics. *Psychopharmacology (Berlin)* 160, 299–306.
- Stip E, Lussier I** (1996). The effect of risperidone on cognition in patients with schizophrenia. *Canadian Journal of Psychiatry* 41, S35–S40.

- Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA** (2003). A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. *Journal of Clinical Psychopharmacology* 23, 400–404.
- Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A** (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. *Archives of General Psychiatry* 57, 968–976.
- Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC** (2000). Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? *Journal of Nervous Disease and Mental Disorder* 188, 518–524.
- Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL** (2002). Does cognitive function improve with quetiapine in comparison to haloperidol? *Schizophrenia Research* 53, 239–248.
- Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL** (2003). The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. *Journal of Clinical Psychiatry* 64, 524–531.
- Zorn SH, Jones SB, Ward KM, Liston DR** (1994). Clozapine is a potent and selective muscarinic M4 receptor agonist. *European Journal of Pharmacology* 269, R1–R2.